CN106729982A - A kind of preparation method of silk fibroin nanosphere - Google Patents
A kind of preparation method of silk fibroin nanosphere Download PDFInfo
- Publication number
- CN106729982A CN106729982A CN201611246562.XA CN201611246562A CN106729982A CN 106729982 A CN106729982 A CN 106729982A CN 201611246562 A CN201611246562 A CN 201611246562A CN 106729982 A CN106729982 A CN 106729982A
- Authority
- CN
- China
- Prior art keywords
- silk fibroin
- water
- silk
- solution
- fibroin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种丝素蛋白纳米球的制备方法。将桑蚕丝或柞蚕丝脱胶后获得丝素蛋白,再将丝素蛋白溶解、透析形成一定浓度的丝素蛋白溶液,将无水乙醇与丝素蛋白水溶液按一定比例混合均匀后冷冻,再经离心、清洗、干燥即可获得丝素蛋白纳米球。将丝素蛋白水溶液与功能蛋白分子如bFGF‑2,IGF‑1,EGF,BMP‑2,OP‑1等混合可制备功能性丝素蛋白微球。该制备过程安全、简便,污染小,可稳定制备粒径均一的丝素蛋白纳米球,适合注射,可用作药物载体、缓释系统等领域。The invention discloses a method for preparing silk fibroin nanospheres. Degumming mulberry silk or tussah silk to obtain silk fibroin, then dissolving and dialyzing the silk fibroin to form a certain concentration of silk fibroin solution, mixing absolute ethanol and silk fibroin aqueous solution in a certain proportion, freezing, and then centrifuging , washing and drying to obtain silk fibroin nanospheres. Functional silk fibroin microspheres can be prepared by mixing silk fibroin aqueous solution with functional protein molecules such as bFGF‑2, IGF‑1, EGF, BMP‑2, OP‑1, etc. The preparation process is safe, convenient and less polluting, and can stably prepare silk fibroin nanospheres with uniform particle diameters, which are suitable for injection and can be used as drug carriers, sustained-release systems and other fields.
Description
(一)技术领域(1) Technical field
本发明涉及一种适用于控制药物缓释的丝素蛋白基纳米球的制备方法,属于生物医学技术领域。The invention relates to a preparation method of silk fibroin-based nanospheres suitable for controlling drug sustained release, and belongs to the technical field of biomedicine.
(二)背景技术(2) Background technology
目前,从生物医用材料的发展趋势看来,人工合成聚合物等不可降解或者降解产物的生物相容性欠佳的材料将逐步减少,而具备良好的生物相容性及体内可吸收性的天然生物材料将受到青睐。天然生物材料在结构、力学、和生物降解性能可控的情况下,在临床应用中具备巨大潜力。At present, from the perspective of the development trend of biomedical materials, non-degradable materials such as synthetic polymers or materials with poor biocompatibility of degradation products will gradually decrease, while natural materials with good biocompatibility and in vivo absorbability will gradually decrease. Biomaterials will be favored. Natural biomaterials have great potential for clinical applications with controllable structure, mechanics, and biodegradation properties.
在众多天然生物材料中,来源于天然蚕丝的丝素蛋白,由于其易加工、生物相容性好,力学强度高,降解速率慢,降解产物为氨基酸等优点,近年来,在组织工程领域被广泛研究。例如,通过编织可以制备网状支架材料用于软组织加强,通过冷冻干燥技术可以制备多孔海绵状支架材料用于骨组织修复,通过高压电喷技术可以制备出微球结构支架材料用于药物缓释等。其中,在药物缓释载体中,丝素蛋白由于降解缓慢,且降解产物为氨基酸,人体可吸收,无毒副作用,提供了一种新的选择。同时,将丝素蛋白与药物复合制备成球状适合注射,同时丝素蛋白分子的特殊分子结构有利于稳定敏感性分子的结构,保护蛋白类功能分子生物活性,有利于临床应用。Among many natural biomaterials, silk fibroin derived from natural silk has been favored in the field of tissue engineering in recent years due to its advantages of easy processing, good biocompatibility, high mechanical strength, slow degradation rate, and degradation products of amino acids. Research extensively. For example, mesh-like scaffold materials can be prepared by weaving for soft tissue reinforcement, porous sponge-like scaffold materials can be prepared for bone tissue repair by freeze-drying technology, and microsphere-structured scaffold materials can be prepared for drug sustained release by high-voltage electrospray technology. Wait. Among them, among the slow-release drug carriers, silk fibroin provides a new choice due to its slow degradation, and the degradation products are amino acids, which can be absorbed by the human body and have no toxic and side effects. At the same time, the silk fibroin and drugs are compounded into a spherical shape suitable for injection, and the special molecular structure of the silk fibroin molecule is conducive to stabilizing the structure of sensitive molecules and protecting the biological activity of protein functional molecules, which is beneficial to clinical application.
在以往的丝素蛋白微球、纳米球的制备过程中,多采用高压电喷法、反相乳液法、喷雾干燥法等方法制备。其中,高压电喷法需要在高压静电场中进行,对设备要求较高,产量较低;反相乳液法容易在材料中引入有机杂质;喷雾干燥法制备的丝素蛋白球粒径均一性有待改进,且工艺复杂,设备要求高。在此,本发明提供了一种简便的丝素蛋白纳米球制备方法,可稳定制备粒径均一的丝素蛋白纳米球。In the previous preparation process of silk fibroin microspheres and nanospheres, methods such as high-pressure electrospray method, inverse emulsion method, and spray drying method were mostly used. Among them, the high-voltage electrospray method needs to be carried out in a high-voltage electrostatic field, which requires high equipment and low yield; the inverse emulsion method is easy to introduce organic impurities into the material; the uniformity of the silk fibroin balls prepared by the spray drying method needs to be improved. Improvement, and the process is complicated and the equipment requirements are high. Here, the present invention provides a simple method for preparing silk fibroin nanospheres, which can stably prepare silk fibroin nanospheres with uniform particle size.
(三)发明内容(3) Contents of the invention
本发明目的是提供一种简便的丝素蛋白纳米球制备方法,快速、稳定地获得粒径均一、分散性良好的丝素蛋白纳米球,同时最大程度减少有机试剂在制备过程中的应用,以减少生产过程中的污染同时提高产物的生物安全性。The purpose of the present invention is to provide a simple method for preparing silk fibroin nanospheres, which can quickly and stably obtain silk fibroin nanospheres with uniform particle size and good dispersion, and at the same time minimize the application of organic reagents in the preparation process, so as to Reduce contamination during production while improving product biosafety.
本发明采用的技术方案是:The technical scheme adopted in the present invention is:
本发明提供一种丝素蛋白纳米球的制备方法,所述方法为:将质量浓度0.1%~5%的丝素蛋白水溶液与无水乙醇(优选4℃预冷1h)充分混合,-25℃~-18℃下冷冻12~24小时,再在4~40℃下解冻,离心(优选4000-15000rpm),取沉淀用去离子水清洗(优选去离子水体积用量为沉淀体积的5-20倍),重复离心和水洗(优选重复3-10次),取最后一次水洗后的沉淀干燥(优选下列方式之一进行干燥:20-25℃室温干燥、40℃真空热干燥或--30℃冷冻干燥),即为丝素蛋白纳米球;所述无水乙醇与丝素蛋白水溶液体积比为1~10:10。The invention provides a method for preparing silk fibroin nanospheres. The method is as follows: fully mix silk fibroin aqueous solution with a mass concentration of 0.1% to 5% and absolute ethanol (preferably precooled at 4°C for 1 hour), and store at -25°C Freeze at ~-18°C for 12-24 hours, then thaw at 4-40°C, centrifuge (preferably 4000-15000rpm), take the precipitate and wash it with deionized water (preferably the volume of deionized water is 5-20 times the volume of the precipitate ), repeated centrifugation and water washing (preferably repeated 3-10 times), and dried the precipitate after the last water washing (preferably one of the following methods for drying: 20-25 ° C room temperature drying, 40 ° C vacuum heat drying or -30 ° C freezing drying), that is, silk fibroin nanospheres; the volume ratio of the absolute ethanol to the silk fibroin aqueous solution is 1-10:10.
进一步,所述丝素蛋白水溶液按如下方法制备:将蚕茧剪碎后浸入质量浓度0.2%无水碳酸钠水溶液(优选无水碳酸钠水溶液体积用量以蚕茧质量计为0.1g/L),煮沸60~120分钟,过滤,取滤饼用去离子水清洗,50℃干燥,获得丝素蛋白纤维;将丝素蛋白纤维溶于9.3mol/L溴化锂水溶液或三元溶液(优选在65-70℃溶解,所述溴化锂水溶液或三元溶液体积用量以能够溶解为准,优选以蚕茧质量计为5-10ml/g)中,以去离子水为透析液进行透析,取透过液用去离子水配制成质量浓度0.1%~5%的丝素蛋白水溶液;所述三元溶液由氯化钙、乙醇、水以体积比为1:2:8混合而成。Further, the silk fibroin aqueous solution is prepared as follows: cut silk cocoons into pieces and immerse them in 0.2% anhydrous sodium carbonate aqueous solution (preferably the volume dosage of anhydrous sodium carbonate aqueous solution is 0.1 g/L based on the mass of silkworm cocoons), boil for 60 ~120 minutes, filter, take the filter cake and wash it with deionized water, dry at 50°C to obtain silk fibroin fiber; dissolve the silk fibroin fiber in 9.3mol/L lithium bromide aqueous solution or ternary solution (preferably dissolved at 65-70°C , the lithium bromide aqueous solution or the ternary solution volumetric dosage is as the criterion that can be dissolved, preferably 5-10ml/g based on silkworm cocoon mass), dialyze with deionized water as the dialysate, and take the permeate to prepare with deionized water A silk fibroin aqueous solution with a mass concentration of 0.1% to 5% is prepared; the ternary solution is formed by mixing calcium chloride, ethanol, and water at a volume ratio of 1:2:8.
进一步,所述丝素蛋白水溶液中添加有功能药物,所述功能药物为生长因子bFGF-2、促生长因子IGF-1、表皮细胞生长因子EGF、重组人骨形态发生蛋白BMP2、成骨蛋白OP-1、阿霉素或盐酸吉西他滨中的一种。Further, functional drugs are added to the silk fibroin aqueous solution, and the functional drugs are growth factor bFGF-2, growth-promoting factor IGF-1, epidermal growth factor EGF, recombinant human bone morphogenetic protein BMP2, osteogenic protein OP- 1. One of doxorubicin or gemcitabine hydrochloride.
进一步,所述功能药物添加量以丝素蛋白水溶液体积计为10-100μg/L,优选10-75μg/L。Furthermore, the added amount of the functional drug is 10-100 μg/L, preferably 10-75 μg/L, based on the volume of the silk fibroin aqueous solution.
进一步,所述功能药物加入到丝素蛋白水溶液中,2-8℃、30-150rpm充分混合5-6分钟,即获得含功能药物的丝素蛋白水溶液。Further, the functional drug is added to the silk fibroin aqueous solution, and mixed thoroughly for 5-6 minutes at 2-8° C. and 30-150 rpm to obtain the silk fibroin aqueous solution containing the functional drug.
进一步,所述方法按如下步骤制备:(1)将桑蚕或柞蚕的蚕茧剪碎加入质量浓度0.2%无水碳酸钠水溶液中煮沸60~120分钟,过滤,滤饼用去离子水洗涤,50℃干燥,获得丝素蛋白纤维;Further, the method is prepared according to the following steps: (1) Cut the cocoons of mulberry silkworm or tussah silkworm into pieces, add them to an aqueous solution of anhydrous sodium carbonate with a mass concentration of 0.2%, boil for 60 to 120 minutes, filter, wash the filter cake with deionized water, and wash it with deionized water for 50 °C drying to obtain silk fibroin fibers;
(2)将丝素蛋白纤维溶于9.3mol/L溴化锂水溶液或三元溶液中(优选在65-70℃溶解),加入透析袋中,以去离子水为透析液透析2-4天,取透过液用去离子水配制成质量浓度0.1%~5%的丝素蛋白水溶液;所述透析袋截留分子量为3500;(2) Dissolve silk fibroin fiber in 9.3mol/L lithium bromide aqueous solution or ternary solution (preferably dissolved at 65-70°C), add it into a dialysis bag, and dialyze with deionized water for 2-4 days, and take The permeated liquid is prepared with deionized water to prepare an aqueous silk fibroin solution with a mass concentration of 0.1% to 5%; the molecular weight cut-off of the dialysis bag is 3500;
(3)将功能药物溶于步骤(2)丝素蛋白水溶液,于2-8℃、30-150rpm充分混合5-6分钟,获得含药丝素蛋白水溶液;所述功能药物为生长因子bFGF-2或重组人骨形态发生蛋白BMP2;(3) Dissolve the functional drug in the silk fibroin aqueous solution in step (2), and mix thoroughly at 2-8°C and 30-150rpm for 5-6 minutes to obtain the drug-containing silk fibroin aqueous solution; the functional drug is the growth factor bFGF- 2 or recombinant human bone morphogenetic protein BMP2;
(4)将丝素蛋白水溶液或含药丝素蛋白水溶液与无水乙醇以体积比1~3:1混合,-20℃下冷冻12~24小时;再于20~35℃下解冻,4000-15000rpm离心后,取沉淀用5-20倍体积的去离子水清洗,重复离心和水洗过程3-10次;取最后一次水洗后的沉淀,通过20-25℃室温干燥、40℃真空热干燥或-30℃冷冻干燥,获得所述丝素蛋白纳米球。(4) Mix silk fibroin aqueous solution or drug-containing silk fibroin aqueous solution with absolute ethanol at a volume ratio of 1-3:1, freeze at -20°C for 12-24 hours; then thaw at 20-35°C, After centrifugation at 15000rpm, take the precipitate and wash it with 5-20 times the volume of deionized water, repeat the centrifugation and water washing process for 3-10 times; take the precipitate after the last water washing, and dry it at room temperature at 20-25°C, vacuum heat drying at 40°C or freeze-drying at -30°C to obtain the silk fibroin nanospheres.
与现有技术相比,本发明的有益效果主要体现在:前期的制备方法多采用高压电喷法或反相乳液法制备,操作较为复杂,且使用大量有机试剂。本发明制备过程操作简便,不涉及高压、极端温度等条件,使用设备简单易得,适合稳定批量生产;其次,所用试剂安全性高污染小,对制备过程环境影响小,材料中残留的试剂可通过水洗除去,有利于提高产物的生物安全性。Compared with the prior art, the beneficial effects of the present invention are mainly reflected in that the previous preparation methods are mostly prepared by high-pressure electrospray method or inverse emulsion method, the operation is relatively complicated, and a large amount of organic reagents are used. The preparation process of the present invention is easy to operate, does not involve high pressure, extreme temperature and other conditions, and the equipment is simple and easy to obtain, which is suitable for stable batch production; secondly, the reagents used have high safety and little pollution, and have little impact on the environment of the preparation process, and the residual reagents in the materials can be It is removed by washing with water, which is beneficial to improve the biological safety of the product.
(四)附图说明(4) Description of drawings
图1丝素蛋白纳米球的扫描电镜图。Fig. 1 SEM images of silk fibroin nanospheres.
图2丝素蛋白纳米球在大鼠皮下注射。(a)皮下注射造模;(b)皮下注射1周后;(c)皮下注射3个月后。Figure 2. Silk fibroin nanospheres were injected subcutaneously in rats. (a) Modeling by subcutaneous injection; (b) 1 week after subcutaneous injection; (c) 3 months after subcutaneous injection.
(五)具体实施方式(5) Specific implementation methods
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此:The present invention is further described below in conjunction with specific embodiment, but protection scope of the present invention is not limited thereto:
实施例1:Example 1:
将50g桑蚕蚕茧剪碎,放入5L沸腾的质量浓度0.2%无水碳酸钠水溶液中,持续煮沸90分钟进行脱胶处理,过滤,收集滤饼,用去离子水反复清洗5遍,除去表面残留的碳酸钠,后50℃干燥,即为丝素蛋白纤维。将干燥后的丝素蛋白纤维溶解于250mL 9.3mol/L溴化锂水溶液(65℃),完全溶解后,将丝素蛋白溶液装入透析袋(截留分子量:3500)中,于去离子水中透析3天,每天换水2次,除去溴化锂。用去离子水将透析后获得的丝素蛋白水溶液浓度调整至质量浓度1%。Cut 50g of silkworm cocoons into pieces, put them into 5L of boiling 0.2% anhydrous sodium carbonate aqueous solution, continue boiling for 90 minutes for degumming treatment, filter, collect filter cake, and wash repeatedly with deionized water 5 times to remove surface residues Sodium carbonate, after drying at 50°C, it is silk fibroin fiber. Dissolve the dried silk fibroin fibers in 250mL 9.3mol/L lithium bromide aqueous solution (65°C). After complete dissolution, put the silk fibroin solution into a dialysis bag (molecular weight cut-off: 3500), and dialyze in deionized water for 3 days , Change the water 2 times a day to remove lithium bromide. The concentration of the silk fibroin aqueous solution obtained after dialysis was adjusted to a mass concentration of 1% with deionized water.
无水乙醇于4℃冰箱中预冷1小时。取10mL无水乙醇加入100mL、质量浓度1%丝素蛋白水溶液中,迅速混合均匀,容器封口后放入-20℃冰箱中冷冻18小时后,取出混合液,于20℃解冻,得到的悬浊液使用离心机于12000rpm离心30分钟后,去掉上清,用100mL去离子水清洗沉淀物,重复该清洗、离心步骤5遍,最后将沉淀物于20℃晾干,即可得到丝素蛋白纳米球。使用扫描电子显微镜观察获得的丝素蛋白纳米球(图1),其分散良好,直径为100nm~200nm。Anhydrous ethanol was pre-cooled in a refrigerator at 4°C for 1 hour. Take 10mL of absolute ethanol and add it to 100mL of 1% silk fibroin aqueous solution, mix quickly and evenly, seal the container and put it in a -20°C refrigerator for 18 hours, take out the mixed solution, and thaw it at 20°C to obtain a suspension After the solution was centrifuged at 12000rpm for 30 minutes in a centrifuge, the supernatant was removed, and the precipitate was washed with 100mL deionized water. The washing and centrifugation steps were repeated 5 times, and finally the precipitate was dried at 20°C to obtain silk fibroin nano ball. Observing the obtained silk fibroin nanospheres ( FIG. 1 ) with a scanning electron microscope, they are well dispersed and have a diameter of 100 nm to 200 nm.
实施例2:Example 2:
将50g柞蚕蚕茧剪碎,放入5L沸腾的质量浓度0.2%无水碳酸钠水溶液中,持续煮沸120分钟进行脱胶处理,过滤,收集滤饼,用去离子水反复清洗获得的丝素蛋白纤维5遍,除去表面残留的碳酸钠,后50℃干燥,即为丝素蛋白纤维。将干燥后的丝素蛋白纤维溶解于500ml、70℃三元溶液(氯化钙/乙醇/水体积比为1:2:8)中,完全溶解后,将丝素蛋白溶液装入透析袋(截留分子量:3500)中,于去离子水去离子水中透析4天,每天换水2次,除去残留溶剂。用去离子水将透析后获得的丝素蛋白水溶液浓度调整至质量浓度5%。Cut 50g tussah silkworm cocoons into pieces, put them into 5L of boiling 0.2% anhydrous sodium carbonate aqueous solution, boil for 120 minutes for degumming treatment, filter, collect filter cake, and repeatedly wash the obtained silk fibroin fibers with deionized water 5 After three times, the residual sodium carbonate on the surface is removed, and then dried at 50°C to obtain silk fibroin fibers. Dissolve the dried silk fibroin fibers in 500ml, 70°C ternary solution (the volume ratio of calcium chloride/ethanol/water is 1:2:8), after completely dissolving, put the silk fibroin solution into a dialysis bag ( MWCO: 3500), dialyze in deionized water for 4 days, change the water twice a day to remove residual solvent. The concentration of the silk fibroin aqueous solution obtained after dialysis was adjusted to a mass concentration of 5% with deionized water.
将5μg bFGF-2溶于100mL、质量浓度5%丝素蛋白水溶液中,于4℃,30rpm速度下混合30分钟,得含bFGF-2丝素蛋白溶液。Dissolve 5 μg of bFGF-2 in 100 mL of an aqueous solution of 5% silk fibroin in mass concentration, and mix at 4° C. for 30 minutes at a speed of 30 rpm to obtain a silk fibroin solution containing bFGF-2.
无水乙醇于4℃冰箱中预冷1小时。取30mL无水乙醇加入100mL含bFGF-2的丝素蛋白溶液中,迅速混合均匀,容器封口后放入-20℃冰箱中冷冻24小时后,取出混合液,于25℃解冻,得到的悬浊液使用离心机于12000rpm离心30分钟后,去掉上清,用100mL去离子水清洗沉淀物,重复该清洗、离心步骤5遍,最后将沉淀物于25℃晾干,即可得到含bFGF2丝素蛋白纳米球,直径为50nm~150nm。Anhydrous ethanol was pre-cooled in a refrigerator at 4°C for 1 hour. Add 30mL of absolute ethanol to 100mL of silk fibroin solution containing bFGF-2, mix quickly and evenly, seal the container and put it in a -20°C refrigerator for 24 hours, take out the mixture, and thaw it at 25°C to obtain a suspension The liquid was centrifuged at 12000rpm for 30 minutes in a centrifuge, the supernatant was removed, the precipitate was washed with 100mL deionized water, the cleaning and centrifugation steps were repeated 5 times, and finally the precipitate was dried at 25°C to obtain silk fibroin containing bFGF2 The protein nanosphere has a diameter of 50nm to 150nm.
实施例3:Example 3:
将50g桑蚕生丝放入5L沸腾的质量浓度0.2%无水碳酸钠水溶液中,持续煮沸60分钟进行脱胶处理,过滤,取滤饼,用去离子水去离子水反复清洗5遍,除去表面残留的碳酸钠,后50℃干燥,即为丝素蛋白纤维。将干燥后的丝素蛋白纤维溶解于500ml、70℃三元溶液(氯化钙/乙醇/水体积比为1:2:8)中,完全溶解后,将丝素蛋白溶液装入透析袋(截留分子量:3500)中,于去离子水中透析4天,每天换水2次,除去残留溶剂。用去离子水将透析后获得的丝素蛋白水溶液浓度调整至质量浓度2%。Put 50g of mulberry silkworm silk into 5L of boiling 0.2% anhydrous sodium carbonate aqueous solution, boil for 60 minutes for degumming treatment, filter, take the filter cake, and wash it repeatedly with deionized water for 5 times to remove surface residues. Sodium carbonate, after drying at 50°C, it is silk fibroin fiber. Dissolve the dried silk fibroin fibers in 500ml, 70°C ternary solution (the volume ratio of calcium chloride/ethanol/water is 1:2:8), after completely dissolving, put the silk fibroin solution into a dialysis bag ( MWCO: 3500), dialyze in deionized water for 4 days, change the water twice a day to remove residual solvent. The concentration of the silk fibroin aqueous solution obtained after dialysis was adjusted to a mass concentration of 2% with deionized water.
将1μg BMP-2溶于质量浓度2%、100mL丝素蛋白水溶液中,于4℃,30rpm速度下混合30分钟,得含BMP-2丝素蛋白溶液。Dissolve 1 μg of BMP-2 in 100 mL of silk fibroin aqueous solution with a mass concentration of 2%, and mix at 4° C. for 30 minutes at a speed of 30 rpm to obtain a silk fibroin solution containing BMP-2.
无水乙醇于4℃冰箱中预冷1小时。取30mL无水乙醇加入100mL含BMP-2丝素蛋白溶液中,迅速混合均匀,容器封口后放入-20℃冰箱中冷冻12小时后,取出混合液,于35℃解冻,得到的悬浊液使用离心机于12000rpm离心30分钟后,去掉上清,用100mL去离子水清洗沉淀物,重复该清洗、离心步骤5遍,最后将沉淀物于40℃真空热干燥,即可得到含BMP-2丝素蛋白纳米球,直径为100nm~200nm。Anhydrous ethanol was pre-cooled in a refrigerator at 4°C for 1 hour. Take 30mL of absolute ethanol and add it to 100mL of BMP-2 silk fibroin protein solution, mix quickly and evenly, seal the container and put it in a -20°C refrigerator for 12 hours, take out the mixed solution, and thaw it at 35°C to obtain a suspension Use a centrifuge to centrifuge at 12000rpm for 30 minutes, remove the supernatant, wash the precipitate with 100mL deionized water, repeat the cleaning and centrifugation steps 5 times, and finally dry the precipitate in vacuum at 40°C to obtain BMP-2-containing Silk fibroin nanospheres with a diameter of 100nm to 200nm.
实施例4:Example 4:
将50g柞蚕生丝放入5L沸腾的质量浓度0.2%无水碳酸钠水溶液中,持续煮沸90分钟进行脱胶处理,过滤,取滤饼,用去离子水去离子水反复清洗5遍,除去表面残留的碳酸钠,后50℃干燥,即为丝素蛋白纤维。将干燥后的丝素蛋白纤维溶解于250mL 9.3mol/L溴化锂水溶液中(65℃),完全溶解后,将丝素蛋白溶液装入透析袋(截留分子量:3500)中,于去离子水中透析4天,每天换水2次,除去残留溶剂。用去离子水将透析后获得的丝素蛋白水溶液浓度调整至质量浓度0.1%。Put 50g tussah silkworm silk into 5L boiling mass concentration 0.2% anhydrous sodium carbonate aqueous solution, continue to boil for 90 minutes to carry out degumming treatment, filter, take filter cake, wash repeatedly 5 times with deionized water and deionized water, remove surface residual Sodium carbonate, after drying at 50°C, it is silk fibroin fiber. Dissolve the dried silk fibroin fiber in 250mL 9.3mol/L lithium bromide aqueous solution (65°C). After completely dissolving, put the silk fibroin solution into a dialysis bag (molecular weight cut-off: 3500), and dialyze in deionized water for 4 Change the water twice a day to remove residual solvent. The concentration of the silk fibroin aqueous solution obtained after dialysis was adjusted to a mass concentration of 0.1% with deionized water.
将7.5μg BMP-2溶于100mL丝素蛋白水溶液中,于4℃,30rpm速度下混合30分钟,得含BMP-2丝素蛋白溶液。Dissolve 7.5 μg of BMP-2 in 100 mL of silk fibroin aqueous solution, and mix for 30 minutes at 4° C. at a speed of 30 rpm to obtain a silk fibroin solution containing BMP-2.
无水乙醇于4℃冰箱中预冷1小时。取100mL无水乙醇加入100mL丝素蛋白水溶液中,迅速混合均匀,容器封口后放入-20℃冰箱中冷冻24小时后,取出混合液,于4℃解冻,得到的悬浊液使用离心机于12000rpm离心30分钟后,去掉上清,用100mL去离子水清洗沉淀物,重复该清洗、离心步骤5遍,最后将沉淀物于-30℃低温真空冷冻干燥,即可得到含BMP-2丝素蛋白纳米球,直径为50nm~250nm。Anhydrous ethanol was pre-cooled in a refrigerator at 4°C for 1 hour. Add 100mL of absolute ethanol to 100mL of silk fibroin aqueous solution, mix quickly and evenly, seal the container and put it in a -20°C refrigerator for 24 hours, take out the mixed solution, thaw at 4°C, and use a centrifuge to obtain the suspension After centrifuging at 12000rpm for 30 minutes, remove the supernatant, wash the precipitate with 100mL deionized water, repeat the cleaning and centrifugation steps 5 times, and finally freeze-dry the precipitate at -30°C in a low-temperature vacuum to obtain silk fibroin containing BMP-2 The protein nanosphere has a diameter of 50nm to 250nm.
实施例5Example 5
软组织修补填充:将经实施例2制备获得的丝素蛋白纳米球分散在注射用生理盐水中,注射到大鼠皮下用于促进软组织再生。大鼠经腹腔麻醉后腹部备皮,在其腹中线的左、右两侧各标记2个注射区域(每只鼠4个注射位点),相邻两点间距离2cm以上。提起注射区皮肤,使用1mL注射器插入针头至真皮深层间,避开血管,注射200μL样品(图2中a)。1周后,处死大鼠,观察注射部位丝素蛋白纳米球的分布以及周围软组织状况(图2中b)。注射部位在1周后仍可清楚的观察到植入的丝素蛋白纳米球隆起,但隆起体积较注射当日减小16%左右,周围组织未见红肿等炎症反应,说明丝素蛋白纳米球已部分被吸收,且植入体内不会引起明显的不良反应,具有良好的生物相容性。植入3月后,外观自然,且未发生化脓等不良反应,仍可观察到少量纳米球存在(图2中c),植入部位被新生纤维组织填充,表明是一种良好的药物载体。Soft tissue repair and filling: the silk fibroin nanospheres prepared in Example 2 were dispersed in saline for injection, and injected subcutaneously into rats to promote soft tissue regeneration. After the rats were anesthetized by abdominal cavity, the abdominal skin was prepared, and 2 injection areas were marked on the left and right sides of the abdominal midline (4 injection sites for each mouse), and the distance between two adjacent points was more than 2 cm. Lift the skin at the injection area, use a 1mL syringe to insert the needle into the deep dermis, avoid blood vessels, and inject 200 μL of the sample (a in Figure 2). One week later, the rats were sacrificed, and the distribution of silk fibroin nanospheres at the injection site and the condition of the surrounding soft tissues were observed (Fig. 2 b). One week after the injection site, the implanted silk fibroin nanospheres could still be clearly observed to bulge, but the volume of the bulge was reduced by about 16% compared with the day of injection, and there was no inflammation such as redness and swelling in the surrounding tissues, which indicated that the silk fibroin nanospheres had completely recovered. It is partially absorbed, and implanted in the body will not cause obvious adverse reactions, and has good biocompatibility. After 3 months of implantation, the appearance was natural, and no adverse reactions such as suppuration occurred. A small amount of nanospheres could still be observed (c in Figure 2), and the implantation site was filled with new fibrous tissue, indicating that it was a good drug carrier.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611246562.XA CN106729982A (en) | 2016-12-29 | 2016-12-29 | A kind of preparation method of silk fibroin nanosphere |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611246562.XA CN106729982A (en) | 2016-12-29 | 2016-12-29 | A kind of preparation method of silk fibroin nanosphere |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106729982A true CN106729982A (en) | 2017-05-31 |
Family
ID=58928930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611246562.XA Pending CN106729982A (en) | 2016-12-29 | 2016-12-29 | A kind of preparation method of silk fibroin nanosphere |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106729982A (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553690A (en) * | 2018-04-13 | 2018-09-21 | 浙江大学 | A kind of porous fibroin microballoon and preparation method thereof for mixing strontium |
| CN108744023A (en) * | 2018-06-15 | 2018-11-06 | 福州大学 | A kind of fibroin albumen medical bio adhesive and preparation method thereof |
| CN108822199A (en) * | 2018-08-02 | 2018-11-16 | 南通纺织丝绸产业技术研究院 | The preparation method of low molecular weight fibroin albumen segment |
| CN109602952A (en) * | 2018-12-27 | 2019-04-12 | 上海北陆医药科技有限公司 | A kind of long-acting slow-release cytoskeleton and preparation method thereof, application |
| CN110003502A (en) * | 2019-04-09 | 2019-07-12 | 西安培华学院 | A kind of fibroin albumen nanosphere and preparation method thereof |
| CN110522942A (en) * | 2019-10-16 | 2019-12-03 | 浙江星月生物科技股份有限公司 | A kind of preparation method of skin repair dressing and skin repair dressing |
| CN111320411A (en) * | 2020-03-02 | 2020-06-23 | 中科如米(北京)生态农业科技发展有限公司 | High-strength shotcrete additive and application thereof |
| CN113730599A (en) * | 2021-10-08 | 2021-12-03 | 苏州大学 | Functional silk fibroin drug carrier and preparation method thereof |
| CN113773796A (en) * | 2021-09-22 | 2021-12-10 | 宁波锋成先进能源材料研究院有限公司 | Nano adhesive and preparation method and application thereof |
| CN113980109A (en) * | 2021-09-13 | 2022-01-28 | 苏州大学 | Preparation method of regenerated silk fibroin material |
| CN114748671A (en) * | 2022-03-22 | 2022-07-15 | 德晟康(苏州)生物科技有限公司 | Composite protein sustained-release hydrocolloid patch and preparation method thereof |
| CN114790300A (en) * | 2022-04-29 | 2022-07-26 | 中国科学院青岛生物能源与过程研究所 | Preparation method of silk fibroin nanoparticles |
| CN114848907A (en) * | 2022-05-12 | 2022-08-05 | 苏州苏豪生物材料科技有限公司 | Growth factor-loaded silk fibroin |
| CN114949349A (en) * | 2022-05-12 | 2022-08-30 | 苏州苏豪生物材料科技有限公司 | Silk fibroin breast patch |
| CN115845146A (en) * | 2022-11-29 | 2023-03-28 | 杭州电子科技大学 | Preparation method of biological ink and preparation method of cell scaffold |
| CN116289295A (en) * | 2023-03-28 | 2023-06-23 | 江阴云智医疗无纺布制品有限公司 | Cotton-milk moisturizing soft towel and production process thereof |
| CN116942563A (en) * | 2023-08-03 | 2023-10-27 | 广西壮族自治区蚕业技术推广站 | Phellinus linteus polysaccharide-loaded nano microsphere and preparation and application thereof |
| CN118458758A (en) * | 2024-07-10 | 2024-08-09 | 河北晶碳科技有限公司 | A method for preparing high-permeability graphite material |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101891962A (en) * | 2010-07-22 | 2010-11-24 | 苏州大学 | Preparation method of silk fibroin porous three-dimensional material |
| CN102488929A (en) * | 2011-12-16 | 2012-06-13 | 东华大学 | Regenerated silk fibroin tissue engineering scaffold containing vascular endothelial growth factor and preparation method thereof |
| WO2013071107A1 (en) * | 2011-11-09 | 2013-05-16 | Trustees Of Tufts College | Injectable silk fibroin particles and uses thereof |
| CN103450488A (en) * | 2013-08-06 | 2013-12-18 | 苏州三和开泰花线织造有限公司 | Preparation method of fibroin nano particles |
| CN103965310A (en) * | 2014-04-21 | 2014-08-06 | 浙江大学 | Self-assembling method for preparing fibroin microspheres |
| WO2014125505A1 (en) * | 2013-02-14 | 2014-08-21 | Council Of Scientific & Industrial Research | Silk based porous scaffold and a process for the preparation thereof |
| CN106046133A (en) * | 2016-05-23 | 2016-10-26 | 东华大学 | Dissolving method for fibroin protein |
-
2016
- 2016-12-29 CN CN201611246562.XA patent/CN106729982A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101891962A (en) * | 2010-07-22 | 2010-11-24 | 苏州大学 | Preparation method of silk fibroin porous three-dimensional material |
| WO2013071107A1 (en) * | 2011-11-09 | 2013-05-16 | Trustees Of Tufts College | Injectable silk fibroin particles and uses thereof |
| CN102488929A (en) * | 2011-12-16 | 2012-06-13 | 东华大学 | Regenerated silk fibroin tissue engineering scaffold containing vascular endothelial growth factor and preparation method thereof |
| WO2014125505A1 (en) * | 2013-02-14 | 2014-08-21 | Council Of Scientific & Industrial Research | Silk based porous scaffold and a process for the preparation thereof |
| CN103450488A (en) * | 2013-08-06 | 2013-12-18 | 苏州三和开泰花线织造有限公司 | Preparation method of fibroin nano particles |
| CN103965310A (en) * | 2014-04-21 | 2014-08-06 | 浙江大学 | Self-assembling method for preparing fibroin microspheres |
| CN106046133A (en) * | 2016-05-23 | 2016-10-26 | 东华大学 | Dissolving method for fibroin protein |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108553690A (en) * | 2018-04-13 | 2018-09-21 | 浙江大学 | A kind of porous fibroin microballoon and preparation method thereof for mixing strontium |
| CN108744023A (en) * | 2018-06-15 | 2018-11-06 | 福州大学 | A kind of fibroin albumen medical bio adhesive and preparation method thereof |
| CN108822199B (en) * | 2018-08-02 | 2023-06-23 | 南通纺织丝绸产业技术研究院 | Preparation method of low molecular weight silk fibroin segment |
| CN108822199A (en) * | 2018-08-02 | 2018-11-16 | 南通纺织丝绸产业技术研究院 | The preparation method of low molecular weight fibroin albumen segment |
| CN109602952A (en) * | 2018-12-27 | 2019-04-12 | 上海北陆医药科技有限公司 | A kind of long-acting slow-release cytoskeleton and preparation method thereof, application |
| CN110003502A (en) * | 2019-04-09 | 2019-07-12 | 西安培华学院 | A kind of fibroin albumen nanosphere and preparation method thereof |
| CN110522942A (en) * | 2019-10-16 | 2019-12-03 | 浙江星月生物科技股份有限公司 | A kind of preparation method of skin repair dressing and skin repair dressing |
| CN111320411A (en) * | 2020-03-02 | 2020-06-23 | 中科如米(北京)生态农业科技发展有限公司 | High-strength shotcrete additive and application thereof |
| CN113980109A (en) * | 2021-09-13 | 2022-01-28 | 苏州大学 | Preparation method of regenerated silk fibroin material |
| CN113773796A (en) * | 2021-09-22 | 2021-12-10 | 宁波锋成先进能源材料研究院有限公司 | Nano adhesive and preparation method and application thereof |
| CN113730599A (en) * | 2021-10-08 | 2021-12-03 | 苏州大学 | Functional silk fibroin drug carrier and preparation method thereof |
| CN114748671A (en) * | 2022-03-22 | 2022-07-15 | 德晟康(苏州)生物科技有限公司 | Composite protein sustained-release hydrocolloid patch and preparation method thereof |
| CN114790300A (en) * | 2022-04-29 | 2022-07-26 | 中国科学院青岛生物能源与过程研究所 | Preparation method of silk fibroin nanoparticles |
| CN114848907A (en) * | 2022-05-12 | 2022-08-05 | 苏州苏豪生物材料科技有限公司 | Growth factor-loaded silk fibroin |
| CN114949349A (en) * | 2022-05-12 | 2022-08-30 | 苏州苏豪生物材料科技有限公司 | Silk fibroin breast patch |
| CN115845146A (en) * | 2022-11-29 | 2023-03-28 | 杭州电子科技大学 | Preparation method of biological ink and preparation method of cell scaffold |
| CN116289295A (en) * | 2023-03-28 | 2023-06-23 | 江阴云智医疗无纺布制品有限公司 | Cotton-milk moisturizing soft towel and production process thereof |
| CN116289295B (en) * | 2023-03-28 | 2024-03-29 | 江阴云智医疗无纺布制品有限公司 | Cotton-milk moisturizing soft towel and production process thereof |
| CN116942563A (en) * | 2023-08-03 | 2023-10-27 | 广西壮族自治区蚕业技术推广站 | Phellinus linteus polysaccharide-loaded nano microsphere and preparation and application thereof |
| CN118458758A (en) * | 2024-07-10 | 2024-08-09 | 河北晶碳科技有限公司 | A method for preparing high-permeability graphite material |
| CN118458758B (en) * | 2024-07-10 | 2024-09-17 | 河北晶碳科技有限公司 | A method for preparing high-permeability graphite material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106729982A (en) | A kind of preparation method of silk fibroin nanosphere | |
| CN103289107B (en) | Preparation method and application of injectable silk fibroin in-situ gel | |
| CN101857729B (en) | Water-insoluble silk fibroin porous material and preparation method thereof | |
| CN103877617B (en) | Two cross-linked hydrogel of injectable fibroin protein-alginate and preparation method thereof and using method | |
| CN106310380B (en) | A kind of nanofiber Silk fibroin gel and preparation method thereof | |
| CN102008756B (en) | Preparation method of nano-fibrous silk fibroin-based porous scaffold | |
| Li et al. | Soft freezing-induced self-assembly of silk fibroin for tunable gelation | |
| CN110812529B (en) | Injectable hydrogel and preparation method thereof | |
| CN106046133B (en) | A kind of dissolving method of silk fibroin | |
| CN101891962A (en) | Preparation method of silk fibroin porous three-dimensional material | |
| CN104004221B (en) | Method for preparing polycaprolactone-keratin composite porous scaffolds | |
| CN102847197A (en) | Three-dimensional silk fibroin scaffold insoluble in water, and preparation and application of three-dimensional silk fibroin scaffold | |
| CN110812688A (en) | A kind of microneedle for transdermal administration and preparation method thereof | |
| CN102218160A (en) | Preparation and application of nerve tissue matrix derived tissue engineering scaffold material | |
| CN106139246A (en) | A kind of regenerated silk azelon support and preparation method thereof | |
| CN113041392A (en) | Preparation method of silk fibroin-gelatin bioactive composite hydrogel loaded with insulin particles | |
| CN104368046B (en) | A fiber-reinforced drug-loaded hydrogel artificial corneal skirt support and its preparation method | |
| Yang et al. | Natural fibrous protein for advanced tissue engineering applications: focusing on silk fibroin and keratin | |
| CN102133432B (en) | Preparation method of silk fibroin micropore bracket | |
| CN117618650A (en) | L-polylactic acid microsphere with high dispersibility and injectability and preparation method thereof | |
| CN106729981B (en) | A kind of silk fibroin nanofiber and its preparation method and application | |
| CN106421902A (en) | Quick-gelatinization silk fibroin solution and preparation method thereof | |
| CN103785060B (en) | Fish skin collagen support loading epidermal growth factors and preparation method thereof | |
| CN108187127A (en) | A kind of polyvinyl alcohol nano suppository and its preparation method and application | |
| CN107217322A (en) | One kind carries medicine long filament and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |